{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:34:17Z","timestamp":1777520057711,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the data on the efficacy of oxcarbazepine (OXC) in bipolar disorder (BD) and to provide recommendations for clinicians on the use of this medication in treating BD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Using the terms oxcarbazepine and bipolar disorder, oxcarbazepine and mania, or oxcarbazepine and bipolar depression, we conducted a computer-aided search of MEDLINE for the years 1950 to 2005.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Case reports, retrospective chart reviews, open prospective studies, and double-blind studies reported the efficacy and effectiveness of OXC in treating BD. The data indicate that OXC has efficacy in treating acute mania and may be a useful add-on in treating acute bipolar depression and in BD prophylaxis. OXC is generally well-tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We recommend using OXC as monotherapy or as add-on therapy in refractory mania, but we recommend it be used predominantly as an add-on treatment for other phases of BD in patients who have not improved with well-established treatments or in patients who have difficulty tolerating adequate dosages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectifs:<\/jats:title>\n                    <jats:p>Examiner les donn\u00e9es sur l'efficacit\u00e9 de l'oxcarbaz\u00e9pine (OXC) dans le trouble bipolaire (TB) et fournir des recommandations aux cliniciens sur l'utilisation de ce m\u00e9dicament pour traiter le TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>M\u00e9thode:<\/jats:title>\n                    <jats:p>Nous avons men\u00e9 une recherche informatique dans MEDLINE recouvrant les ann\u00e9es 1950 \u00e0 2005, \u00e0 l'aide des termes oxcarbaz\u00e9pine et trouble bipolaire, oxcarbaz\u00e9pine et manie, ou oxcarbaz\u00e9pine et d\u00e9pression bipolaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>R\u00e9sultats:<\/jats:title>\n                    <jats:p>Des \u00e9tudes de cas, des \u00e9tudes de dossiers r\u00e9trospectives, des \u00e9tudes prospectives ouvertes et des \u00e9tudes \u00e0 double insu portaient sur l'efficacit\u00e9 et l'utilit\u00e9 de l'OXC dans le traitement du TB. Les donn\u00e9es indiquent que l'OXC est efficace pour traiter la manie aigu\u00eb et peut \u00eatre un ajout utile pour traiter la d\u00e9pression bipolaire aigu\u00eb et pour la prophylaxie du TB. L'OXC est g\u00e9n\u00e9ralement bien tol\u00e9r\u00e9e.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Nous recommandons l'utilisation de l'OXC comme monoth\u00e9rapie ou comme ajout \u00e0 la th\u00e9rapie de la manie r\u00e9fractaire, mais nous recommandons de l'utiliser principalement comme ajout au traitement d'autres phases du TB, chez des patients qui ne se sont pas am\u00e9lior\u00e9s avec les traitements bien \u00e9tablis ou chez les patients qui ont de la difficult\u00e9 \u00e0 tol\u00e9rer les doses ad\u00e9quates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/070674370605100809","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T02:59:06Z","timestamp":1484103546000},"page":"540-545","source":"Crossref","is-referenced-by-count":29,"title":["Oxcarbazepine in the Treatment of Bipolar Disorder: A Review"],"prefix":"10.1177","volume":"51","author":[{"given":"Wetid","family":"Pratoomsri","sequence":"first","affiliation":[{"name":"Clinical Research Fellow, Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi N","family":"Yatham","sequence":"additional","affiliation":[{"name":"Professor, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia; Director, Mood Disorders Clinical Research Unit, University of British Columbia, Vancouver, British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Bond","sequence":"additional","affiliation":[{"name":"Consultant Psychiatrist, Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond W","family":"Lam","sequence":"additional","affiliation":[{"name":"Professor and Head, Division of Clinical Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia; Director, Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ho","family":"Sohn","sequence":"additional","affiliation":[{"name":"Clinical Research Fellow, Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,7,1]]},"reference":[{"key":"bibr1-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014571"},{"key":"bibr2-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291796004461"},{"key":"bibr3-070674370605100809","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4088\/JCP.v65n0105","volume":"65","author":"Yatham LN","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"bibr4-070674370605100809","first-page":"139","volume-title":"Anticonvulsants in affective disorders","author":"Muller AA","year":"1984"},{"key":"bibr5-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.07.004"},{"key":"bibr6-070674370605100809","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342120-00002"},{"key":"bibr7-070674370605100809","first-page":"147","volume-title":"Anticonvulsants in mood disorders","author":"Ketter TA","year":"1994"},{"key":"bibr8-070674370605100809","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630060-00001"},{"key":"bibr9-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb05938.x"},{"key":"bibr10-070674370605100809","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.v64n0301","volume":"64","author":"White HS","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"bibr11-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb03702.x"},{"key":"bibr12-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000123695.22623.32"},{"key":"bibr13-070674370605100809","volume-title":"Depression in primary care. AHCPR Pub. No. 93 0551","author":"United States Depression Guideline Panel","year":"1993"},{"key":"bibr14-070674370605100809","volume-title":"Structured group psychotherapy for bipolar disorder: The life goals program","author":"Mark S","year":"2003"},{"key":"bibr15-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.54.8.1166-a"},{"key":"bibr16-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D442"},{"key":"bibr17-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200109000-00005"},{"key":"bibr18-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.10.1793"},{"key":"bibr19-070674370605100809","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0813"},{"key":"bibr20-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.40104.x"},{"key":"bibr21-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2003.00047.x"},{"key":"bibr22-070674370605100809","volume-title":"155th Annual Meeting of the American Psychiatric Association","author":"Reinstein MJ","year":"2002"},{"key":"bibr23-070674370605100809","volume-title":"5th Annual Meeting of the European College of Neuropsychopharmacology","author":"Munasifi FA","year":"2002"},{"key":"bibr24-070674370605100809","volume-title":"5th International Conference on Bipolar Disorder","author":"Platt DE","year":"2003"},{"key":"bibr25-070674370605100809","volume-title":"155th Annual Meeting of the American Psychiatric Association","author":"Nars SJCM","year":"2002"},{"key":"bibr26-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00253.x"},{"key":"bibr27-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003754"},{"key":"bibr28-070674370605100809","first-page":"208","volume-title":"Anticonvulsants in affective disorders","author":"Velikonja MHK","year":"1984"},{"key":"bibr29-070674370605100809","volume-title":"155th Annual Meeting of the American Psychiatric Association","author":"Munoz RA","year":"2002"},{"key":"bibr30-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00407-X"},{"key":"bibr31-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.02228.x"},{"key":"bibr32-070674370605100809","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323100-00006"},{"key":"bibr33-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(83)90067-9"},{"key":"bibr34-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(85)90022-9"},{"key":"bibr35-070674370605100809","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00004850-199004000-00002","volume":"5","author":"Emrich HM","year":"1990","journal-title":"Int Clin Psychopharmacol"},{"key":"bibr36-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1007\/BF02440853"},{"key":"bibr37-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02392.x"},{"key":"bibr38-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(88)90018-6"},{"key":"bibr39-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1177\/096032718900800501"},{"key":"bibr40-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1993.tb04106.x"},{"key":"bibr41-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.52.4.472"},{"key":"bibr42-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.904.34513"},{"key":"bibr43-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2005.07.017"},{"key":"bibr44-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00338-5"},{"key":"bibr45-070674370605100809","first-page":"45","volume-title":"Anticonvulsants in affective disorders","author":"Emrich HM","year":"1984"},{"key":"bibr46-070674370605100809","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115020-00005"},{"key":"bibr47-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04234.x"},{"key":"bibr48-070674370605100809","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-5050(02)00017-3"}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674370605100809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/070674370605100809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:10:14Z","timestamp":1777392614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/070674370605100809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1177\/070674370605100809"],"URL":"https:\/\/doi.org\/10.1177\/070674370605100809","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}